Wearable data collaboration gives AbbVie insight into MS trials

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Zerbor)
(Image: Getty/Zerbor)

Related tags AbbVie CNS Data Multiple sclerosis Clinical trials

AbbVie is collaborating with MC10 to use its wearable system to gather insights on possible metrics and digital biomarkers that can be applied to MS trials.

The healthcare technology company will partner with AbbVie in an aim to examine data collected from MC10’s BioStamp nPoint system as potential insights into multiple sclerosis (MS) clinical studies.

Ben Schlatka, CEO of MC10 told us that the BioStamp nPoint system is a wearable that continuously collects physiological data outside of the clinic. This system, “enables a more complete picture of a subject’s health throughout a clinical trial,” he added.

The wearable has 44 endpoints generated by MC10’s algorithms and also has capabilities to collect raw sensor data from any location on the body which Schlatka said can enable the exploration of new digital biomarkers, which according to Schlatka, can provide “invaluable data related to treatment effect and quality of life.”

BioStamp nPoint is also capable of remote data collection so subjects can apply included sensors, complete daily prescribed activities, and log patient-reported outcomes while the wearable automatically uploads its collected data for analysis by the sponsor.

Schlatka told us that insights gained from this partnership can be applicable for MS trials as neurodegenerative diseases often result in a progressive loss of motor control. “Passive, continuous data collection allows for the measurement of motor control and quality of life metrics such as sleep duration and actigraphy in more natural settings,”​ he added.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us

Products

View more

Webinars